NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $6.09 +0.06 (+1.00%) As of 02:05 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Precision BioSciences Stock (NASDAQ:DTIL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Precision BioSciences alerts:Sign Up Key Stats Today's Range$5.98▼$6.1550-Day Range$6.03▼$8.8552-Week Range$3.53▼$9.62Volume121,835 shsAverage Volume312,919 shsMarket Capitalization$168.12 millionP/E RatioN/ADividend YieldN/APrice Target$32.25Consensus RatingModerate Buy Company Overview Precision BioSciences, Inc. is a biotechnology company developing gene-editing therapies for serious diseases. The company’s work is based primarily on its proprietary ARCUS platform, which uses engineered nucleases designed to make precise changes to DNA inside the body. Precision BioSciences is focused on in vivo gene editing programs addressing conditions including chronic hepatitis B, Duchenne muscular dystrophy and alpha-1 antitrypsin deficiency. Its development efforts are intended to remove, insert or repair genetic material and potentially provide durable treatments after a single administration. Founded in 2006 and headquartered in Durham, North Carolina, the company has also pursued cell therapy programs and strategic collaborations to apply its gene-editing technology to additional therapeutic areas. Precision BioSciences serves global biopharmaceutical and healthcare markets through its research, development and partnership activities.AI Generated. May Contain Errors. Read More Precision BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreDTIL MarketRank™: 3.175931981685 of 5 starsPrecision BioSciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 330th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingPrecision BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPrecision BioSciences has a consensus price target of $32.25, representing about 431.7% upside from its current price of $6.07.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 2 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($3.33) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Precision BioSciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.36% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 8.81.Change versus previous monthShort interest in Precision BioSciences has recently increased by 13.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.47 News SentimentPrecision BioSciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Precision BioSciences this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.1 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Precision BioSciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $29,501.00 in company stock, which represents 0.0176% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,501.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.70% of the stock of Precision BioSciences is held by insiders.Percentage Held by Institutions37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DTIL Stock News HeadlinesPrecision BioSciences Inc (DTIL)October 13 at 8:05 AM | in.investing.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Stock Rated "Moderate Buy" by Wall Street AnalystsOctober 12 at 4:15 AM | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 15 at 1:00 AM | InvestorPlace (Ad)Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026October 8, 2026 | businesswire.comPrecision BioSciences (NASDAQ:DTIL) Director Geno Germano Purchases 2,609 Shares of Company StockSeptember 30, 2026 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE) and Precision BioSciences (DTIL)September 30, 2026 | theglobeandmail.comPrecision Biosciences Inc.September 23, 2026 | barrons.comPrecision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD StudyAugust 24, 2026 | businesswire.comSee More Headlines DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $4.16 at the start of the year. Since then, DTIL stock has increased by 45.8% and is now trading at $6.0650. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) released its earnings results on Thursday, August, 6th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.46. Precision BioSciences had a negative trailing twelve-month return on equity of 72.52% and a negative net margin of 96.73%. When did Precision BioSciences' stock split? Precision BioSciences shares reverse split before market open on Wednesday, February 14th 2024.The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Kaleido Biosciences (KLDO), Tesla (TSLA), Micron Technology (MU), Advanced Micro Devices (AMD) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings8/06/2026Today10/15/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, DTIL's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DTIL CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees67Year Founded2006Price Target and Rating Average Price Target for Precision BioSciences$32.25 High Price Target$60.00 Low Price Target$19.00 Potential Upside/Downside+430.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.72 million Net Margins-96.73% Pretax Margin-119.00% Return on Equity-72.52% Return on Assets-32.25% Debt Debt-to-Equity Ratio0.50 Current Ratio12.82 Quick Ratio12.82 Sales & Book Value Annual Sales$45.06 million Price / Sales3.73 Cash FlowN/A Price / Cash FlowN/A Book Value$4.03 per share Price / Book1.51Miscellaneous Outstanding Shares27,602,000Free Float26,857,000Market Cap$167.96 million OptionableNo Data Beta1.27 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:DTIL) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DTIL Stock Alerts